CDER “Comprehensive” Reorganization To Follow After CBER-CDER Merger
This article was originally published in The Tan Sheet
Executive Summary
CDER plans to reorganize into indication-based divisions following the merger between FDA's drug and biologics centers, Office of New Drugs Director John Jenkins, MD, said during the Biotechnology Industry annual meeting in Washington, D.C. June 24
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning